230 related articles for article (PubMed ID: 20361239)
1. Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.
Unwalla RJ; Cross JB; Salaniwal S; Shilling AD; Leung L; Kao J; Humblet C
J Comput Aided Mol Des; 2010 Mar; 24(3):237-56. PubMed ID: 20361239
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6.
de Graaf C; Oostenbrink C; Keizers PH; van Vugt-Lussenburg BM; van Waterschoot RA; Tschirret-Guth RA; Commandeur JN; Vermeulen NP
Curr Drug Metab; 2007 Jan; 8(1):59-77. PubMed ID: 17266524
[TBL] [Abstract][Full Text] [Related]
3. Analysis of CYP2D6 substrate interactions by computational methods.
Ito Y; Kondo H; Goldfarb PS; Lewis DF
J Mol Graph Model; 2008 Feb; 26(6):947-56. PubMed ID: 17764997
[TBL] [Abstract][Full Text] [Related]
4. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent.
Lussenburg BM; Keizers PH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2005 Oct; 70(8):1253-61. PubMed ID: 16135359
[TBL] [Abstract][Full Text] [Related]
5. Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications.
Ford KA; Ryslik G; Sodhi J; Halladay J; Diaz D; Dambach D; Masuda M
Drug Metab Rev; 2015 Aug; 47(3):291-319. PubMed ID: 26024250
[TBL] [Abstract][Full Text] [Related]
6. Exploration of enzyme-ligand interactions in CYP2D6 & 3A4 homology models and crystal structures using a novel computational approach.
Kjellander B; Masimirembwa CM; Zamora I
J Chem Inf Model; 2007; 47(3):1234-47. PubMed ID: 17381082
[TBL] [Abstract][Full Text] [Related]
7. Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6.
Kirton SB; Kemp CA; Tomkinson NP; St-Gallay S; Sutcliffe MJ
Proteins; 2002 Nov; 49(2):216-31. PubMed ID: 12211002
[TBL] [Abstract][Full Text] [Related]
8. Integrated structure- and ligand-based in silico approach to predict inhibition of cytochrome P450 2D6.
Martiny VY; Carbonell P; Chevillard F; Moroy G; Nicot AB; Vayer P; Villoutreix BO; Miteva MA
Bioinformatics; 2015 Dec; 31(24):3930-7. PubMed ID: 26315915
[TBL] [Abstract][Full Text] [Related]
9. A molecular model of CYP2D6 constructed by homology with the CYP2C5 crystallographic template: investigation of enzyme-substrate interactions.
Lewis DF; Dickins M; Lake BG; Goldfarb PS
Drug Metabol Drug Interact; 2003; 19(3):189-210. PubMed ID: 14682610
[TBL] [Abstract][Full Text] [Related]
10. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6.
de Groot MJ; Ackland MJ; Horne VA; Alex AA; Jones BC
J Med Chem; 1999 Oct; 42(20):4062-70. PubMed ID: 10514276
[TBL] [Abstract][Full Text] [Related]
11. Structure-based site of metabolism prediction for cytochrome P450 2D6.
Moors SL; Vos AM; Cummings MD; Van Vlijmen H; Ceulemans A
J Med Chem; 2011 Sep; 54(17):6098-105. PubMed ID: 21797232
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening.
Mo SL; Liu WF; Li CG; Zhou ZW; Luo HB; Chew H; Liang J; Zhou SF
Curr Pharm Biotechnol; 2012 Jul; 13(9):1640-704. PubMed ID: 22039821
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous Ligand Access Events to Membrane-Bound Cytochrome P450 2D6 Sampled at Atomic Resolution.
Fischer A; Smieško M
Sci Rep; 2019 Nov; 9(1):16411. PubMed ID: 31712722
[TBL] [Abstract][Full Text] [Related]
14. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
Wang B; Yang LP; Zhang XZ; Huang SQ; Bartlam M; Zhou SF
Drug Metab Rev; 2009; 41(4):573-643. PubMed ID: 19645588
[TBL] [Abstract][Full Text] [Related]
15. Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
Venhorst J; ter Laak AM; Commandeur JN; Funae Y; Hiroi T; Vermeulen NP
J Med Chem; 2003 Jan; 46(1):74-86. PubMed ID: 12502361
[TBL] [Abstract][Full Text] [Related]
16. Molecular Dynamics Simulations Reveal Structural Differences among Allelic Variants of Membrane-Anchored Cytochrome P450 2D6.
Fischer A; Don CG; Smieško M
J Chem Inf Model; 2018 Sep; 58(9):1962-1975. PubMed ID: 30126275
[TBL] [Abstract][Full Text] [Related]
17. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108.
de Groot MJ; Vermeulen NP; Kramer JD; van Acker FA; Donné-Op den Kelder GM
Chem Res Toxicol; 1996; 9(7):1079-91. PubMed ID: 8902262
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of human cytochrome P450 2D6.
Rowland P; Blaney FE; Smyth MG; Jones JJ; Leydon VR; Oxbrow AK; Lewis CJ; Tennant MG; Modi S; Eggleston DS; Chenery RJ; Bridges AM
J Biol Chem; 2006 Mar; 281(11):7614-22. PubMed ID: 16352597
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of human cytochrome P450 2D6 with prinomastat bound.
Wang A; Savas U; Hsu MH; Stout CD; Johnson EF
J Biol Chem; 2012 Mar; 287(14):10834-43. PubMed ID: 22308038
[TBL] [Abstract][Full Text] [Related]
20. The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations.
Bapiro TE; Hasler JA; Ridderström M; Masimirembwa CM
Biochem Pharmacol; 2002 Nov; 64(9):1387-98. PubMed ID: 12392820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
